Cullinan Oncology Llc Stock In The News

CGEM Stock  USD 8.79  0.13  1.46%   
Our overall analysis of Cullinan Oncology's news coverage and content from conventional and social sources shows investors' bearish mood towards Cullinan Oncology LLC. The specific impact of Cullinan Oncology news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Cullinan Oncology's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Cullinan Oncology headlines in addition to utilizing other, more conventional financial analysis modules. Check out Cullinan Oncology Backtesting and Cullinan Oncology Hype Analysis.

Cullinan Oncology Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
https://www.globenewswire.com/news-release/2025/02/27/3033704/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
 Neutral
Yahoo News
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
https://finance.yahoo.com/news/amgens-rocatinlimab-data-beats-placebo-120401801.html
 Bullish
Yahoo News
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
https://finance.yahoo.com/news/mercks-1-3b-deal-potential-191810100.html
 Bullish
Yahoo News
13 Best Booming Stocks to Buy Right Now
https://finance.yahoo.com/news/13-best-booming-stocks-buy-142154910.html
 Bullish
Yahoo News
Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares
https://finance.yahoo.com/news/insider-sell-cullinan-oncology-incs-000210431.html
 Bullish
Yahoo News
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/cullinan-oncology-present-42nd-annual-215300399.html
 Bullish
Yahoo News
Cullinan Oncology Announces First Patien...
https://finance.yahoo.com/news/cullinan-oncology-announces-first-patient-213000521.html
 Neutral
Macroaxis News: globenewswire.com
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/08/2776057/0/en/Cullinan-Oncology-Provides-Corporate-Update-and-Reports-Third-Quarter-2023-Financial-Results.html
 Neutral
Yahoo News
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
https://finance.yahoo.com/news/cullinan-oncology-provides-corporate-reports-120000312.html
 Neutral
Macroaxis News: globenewswire.com
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
https://www.globenewswire.com/news-release/2023/11/03/2773339/0/en/Cullinan-Oncology-to-Present-Data-Demonstrating-Progress-Across-Its-Broad-Immunotherapy-Pipeline-at-SITC-2023.html
 Neutral

Cullinan Oncology LLC Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Cullinan and other traded companies coverage with news coverage. We help investors stay connected with Cullinan headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Cullinan Stock performance. Please note that trading solely based on the Cullinan Oncology LLC hype is not for everyone as timely availability and quick action are needed to avoid losses.
Cullinan Oncology's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Cullinan Oncology LLC investors visualize upcoming and past events in order to time the market based on Cullinan Oncology LLC noise-free hype analysis.
Cullinan Oncology stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Cullinan earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Cullinan Oncology that are available to investors today. That information is available publicly through Cullinan media outlets and privately through word of mouth or via Cullinan internal channels. However, regardless of the origin, that massive amount of Cullinan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cullinan Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cullinan Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cullinan Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cullinan Oncology alpha.

Cullinan Largest EPS Surprises

Earnings surprises can significantly impact Cullinan Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-10
2021-06-30-0.41-0.360.0512 
2023-03-09
2022-12-31-0.66-0.590.0710 
2021-05-14
2021-03-310.07-0.0017-0.0717102 
2024-11-06
2024-09-30-0.81-0.690.1214 
2024-05-15
2024-03-31-0.99-0.860.1313 
2023-08-10
2023-06-30-0.97-0.820.1515 
View All Earnings Estimates

Cullinan Oncology Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Cullinan Oncology LLC Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Google News at Macroaxis
3rd of March 2025
Cullinan Oncology stock hits 52-week low at 8.35 - Investing.com
at news.google.com 
Simply Wall St News at Macroaxis
27th of February 2025
Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans
at simplywall.st 
Macroaxis News
25th of February 2025
Disposition of 3756 shares by Sumer Jacquelyn L of Cullinan Oncology at 8.53 subject to Ru...
at MacroaxisInsider 
news
11th of February 2025
How Is Cullinan Therapeutics Advancing in the Oncology Sector
at kalkinemedia.com 
Yahoo News
31st of January 2025
Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans
at finance.yahoo.com 
Yahoo News
29th of January 2025
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint ...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
8th of January 2025
Insider Sell Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics Inc
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cullinan Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cullinan Oncology's short interest history, or implied volatility extrapolated from Cullinan Oncology options trading.
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out Cullinan Oncology Backtesting and Cullinan Oncology Hype Analysis.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Return On Assets
(0.22)
Return On Equity
(0.32)
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.